Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group

New therapeutic strategies are needed for pediatric acute myeloid leukemia (AML) to reduce disease recurrence and treatment-related morbidity. The Children’s Oncology Group Phase III AAML1031 trial tested whether the addition of bortezomib to standard chemotherapy improves survival in pediatric pati...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Haematologica
Prif Awduron: Aplenc, Richard, Meshinchi, Soheil, Sung, Lillian, Alonzo, Todd, Choi, John, Fisher, Brian, Gerbing, Robert, Hirsch, Betsy, Horton, Terzah, Kahwash, Samir, Levine, John, Loken, Michael, Brodersen, Lisa, Pollard, Jessica, Raimondi, Susana, Kolb, Edward Anders, Gamis, Alan
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Ferrata Storti Foundation 2020
Pynciau:
Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7327649/
https://ncbi.nlm.nih.gov/pubmed/32029509
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.220962
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg